Patents Assigned to University of Utah, The
  • Patent number: 11193169
    Abstract: The present invention provides for methods of determining telomere length of an organism and correlating the measured telomere length with mortality risk associated with telomere length in a population. The presence of shorter telomeres is associated with an increased mortality rate and increased susceptibility to certain types of diseases for an individual member of a human population.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: December 7, 2021
    Assignee: University of Utah Research Foundation
    Inventor: Richard Cawthon
  • Patent number: 11191875
    Abstract: The invention is directed to a composition comprising a fibrin hydrogel conjugated to peptides of laminin-111 (L1) and methods for repairing damaged salivary tissue using the composition.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: December 7, 2021
    Assignees: UNIVERSITY OF UTAH RESEARCH FOUNDATION, UNIVERSITY AT BUFFALO
    Inventors: Olga Baker, Kihoon Nam, Pedro Lei, Stelios Andreadis
  • Patent number: 11185271
    Abstract: A method of manufacturing a micro-molded electrode (160) having multiple individually addressable sensors (140) along a shaft (180) can include forming a recess in a mold substrate, depositing a structural material therein, depositing a conductive material at specific locations, providing a coating (190), and removing the mold substrate. A micro-molded electrode (160) having a base (170) tapering to at least one shaft (180) can include an electrode substrate, multiple individually addressable sensors (140), and a coating (190).
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: November 30, 2021
    Assignee: University of Utah Research Foundation
    Inventors: Sandeep Negi, Rajmohan Bhandari
  • Patent number: 11180538
    Abstract: The invention provides a plasmid comprising two or more anti-obesity genes. Also provided by the invention are compositions and host cells comprising the plasmid and methods of increasing the metabolic activity in a mammal. The invention provides a plasmid comprising two or more of (a) a nucleic acid sequence encoding islet amyloid polypeptide (IAPP), (b) a nucleic acid sequence encoding leptin (LEP), and (c) a nucleic acid sequence encoding fibronectin type III domain containing 5 (FNDC5).
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: November 23, 2021
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: You Han Bae, Hongsuk Park, Sungpil Cho
  • Patent number: 11175293
    Abstract: Described herein are diagnostic and control fusion protein reagents and methods for use thereof in simple rapid and inexpensive hemagglutinin assays for the detection of subject antibodies directed to the SARS-CoV-2 virus.
    Type: Grant
    Filed: January 4, 2021
    Date of Patent: November 16, 2021
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Hans Haecker, Vanessa Redecke
  • Patent number: 11168359
    Abstract: Disclosed herein are methods and compositions for determining the copy number of a first target nucleic acid as compared to the copy number of a second target nucleic acid in a single well with a single detection label. For example, disclosed herein are methods and compositions for determining the copy number of a first target nucleic acid as compared to the copy number of a second target nucleic acid by a monochrome multiplex quantitative PCR (MMQPCR) in a single well with a single detection label.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: November 9, 2021
    Assignee: University of Utah Research Foundation
    Inventor: Richard M. Cawthon
  • Patent number: 11162781
    Abstract: An interferometry system includes a plurality of coherent light sources that each generate a beam of coherent light. Separate waveguide pathways are optically associated with each coherent light source. Each separate waveguide pathway has an endpoint configured to emit at least a portion of the beam of coherent light from the associated light source. A plurality of photodetectors is optically associated with waveguide pathways. In some cases, a retroreflector receives the light emitted from the endpoints, modulates the received light, and directs the modulated light back to the endpoints. The modulated light and a portion of the coherent light reflected from the endpoint of the waveguide pathway receiving the modulated light is directed a photodetector.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: November 2, 2021
    Assignee: University of Utah Research Foundation
    Inventor: Clayton C. Williams
  • Patent number: 11154551
    Abstract: Disclosed herein are methods for treating a cancer and a method for sensitizing a cancer to a chemotherapeutic agent. Each method administers an agent that selectively inhibits HDAC1 and HDAC2 to a subject in need thereof. Also disclosed herein are methods for determining if a cancer is sensitive to an agent that selectively inhibits HDAC1 and HDAC2 and methods for monitoring the efficacy of a treatment for a cancer that includes administration of an agent that selectively inhibits HDAC1 and HDAC2.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: October 26, 2021
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventor: Srividya Bhaskara
  • Patent number: 11154186
    Abstract: A catheter for imaging and treating a selected tissue and method of use is provided. Imaging, and treatment assemblies may be co-located at a distal end of a single catheter. The imaging assembly may include at least a portion of a confocal microscope. The treatment assembly may include at least a portion of the imaging assembly. A method of treating a selected tissue is also provided. The method may be performed using a single catheter. The imaging and treatment steps of the method may be performed simultaneously.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: October 26, 2021
    Assignee: University of Utah Research Foundation
    Inventors: Frank B. Sachse, Robert W. Hitchcock, Nassir F. Marrouche, Nathan J. Knighton, Chao Huang
  • Patent number: 11155577
    Abstract: In one aspect, the invention relates to compositions comprising stapled peptides, methods of making same, pharmaceutical compositions comprising same, and methods of treating various diseases, including, but not limited to, metabolic disorders such as diabetes, and cancers. The disclosed compounds comprise stapled peptides, including, but not limited to, stapled glucagon, axin, and p53 peptide homologues, which are useful as therapeutic agents for a variety of diseases as disclosed herein. The disclosed methods are useful in the preparation of a variety of stapled peptides, including stapled peptide homologues of glucagon, axin, and p53. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: October 26, 2021
    Assignee: University of Utah Research Foundation
    Inventors: Danny Hung-Chieh Chou, Yuanxiang Wang
  • Publication number: 20210322470
    Abstract: An ophthalmic composition or dosage form can include a therapeutically effective amount of a cross-linking agent and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat an ophthalmic condition by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.
    Type: Application
    Filed: June 28, 2021
    Publication date: October 21, 2021
    Applicant: University of Utah Research Foundation
    Inventors: Balamurali K. Ambati, Hironori Uehara, Santosh Muddana
  • Patent number: 11135231
    Abstract: Methods and compositions for preventing and/or treating diseases and conditions caused by certain apicomplexan infections are provided. The methods involve administering/providing to a subject one or more of tartrolon D and E, including isomers thereof. Exemplary apicomplexan infections that are prevented/treated by the compounds of the invention include those caused by Cryptosporidium, Babesia, Cyclospora, Isospora, Plasmodium, Sarcocystis, Besnoitia, Hammondia, Neospora, Theileria and Toxoplasma.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: October 5, 2021
    Assignees: Washington State University, Tufts Medical Center, Inc., University of Utah
    Inventors: Roberta O'Connor, Eric W. Schmidt
  • Patent number: 11130679
    Abstract: The disclosure extends to biodegradable hollow nanoparticles, and systems, methods, devices, and processes for producing the same. The disclosure includes a method of preparing a hollow mesoporous nanoparticle by providing a plurality of silica core particles. Each of the plurality of silica core particles comprises a diameter within a range of about 600 nanometers to about 30 nanometers. The method further includes synthesizing a mesoporous silica shell around the plurality of silica core particles forming a plurality of mesoporous coated silica core particles. Further, the method provides for etching the plurality of mesoporous coated silica core particles with an aqueous solution of sodium carbonate and water to remove the silica core particle from the plurality of mesoporous coated silica core particles forming a plurality of hollow mesoporous particles. The method also includes diffusing a payload into the plurality of hollow mesoporous particles in an aqueous solution.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: September 28, 2021
    Assignee: University of Utah Research Foundation
    Inventors: Seyyed Pouya Hadipour Moghaddam, Hamidreza Ghandehari
  • Patent number: 11124841
    Abstract: Described herein are methods and compositions useful in detecting, diagnosing and treating small cell lung cancer. Transgenic animal models and cell lines are disclosed for the study of a small cell lung cancer subtype. Methods of screening and identifying active agents for the treatment of a small cell lung cancer subtype as well as methods of identifying patients susceptible to treatment with aurora kinase inhibitors are also provided.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: September 21, 2021
    Assignee: University Of Utah Research Foundation
    Inventors: Trudy Oliver, Martin Sos, Rob Wechsler-Reya
  • Patent number: 11118212
    Abstract: The invention is directed to methods for identifying one or more introns of a gene that are rapidly processed from a nascent RNA molecule transcribed from the gene, which allows for the detection of allele-specific expression of a gene in a single cell.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: September 14, 2021
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventor: Christopher Gregg
  • Patent number: 11104929
    Abstract: The disclosure provides recombinant cells and methods for producing a ribosomally synthesized and posttranslationally modified peptide (RiPP), as well as RiPP libraries and methods for producing RiPP libraries.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: August 31, 2021
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventor: Eric Schmidt
  • Patent number: 11094221
    Abstract: A method and system of visually communicating navigation instructions can use translational and rotational arrow cues (TRAC) defined in an object-centric frame while displaying a single principal view that approximates the human's egocentric view of the actual object. A visual guidance system and method can be used to pose a physical object within three-dimensional (3D) space. Received pose data (402) indicates a current position and orientation of a physical object within 3D space, such that the pose data can provide a view of the physical object used to generate a virtual view of the physical object in 3D space. At least two of six degrees of freedom (6DoF) error can be calculated (404) based on a difference between the current position of the physical object and a target pose of the physical object.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: August 17, 2021
    Assignee: University of Utah Research Foundation
    Inventors: Jacob J Abbott, David E. Usevitch
  • Patent number: 11091800
    Abstract: A method of increasing detection of low-abundant fragments of cell-free DNA (ccfDNA) in a biological sample is disclosed and discussed. Such a method can include isolating an initial fraction of ccfDNA fragments from a biological sample, ligating a unique molecular identifier (UMI) to each of the ccfDNA fragments in the initial fraction, amplifying the plurality of ccfDNA fragments to generate a ccfDNA library, isolating a short fraction of ccfDNA fragments from the ccfDNA library, where the ccfDNA fragments in the short fraction are limited to a size of less than or equal to 160 base pairs (bp), amplifying the ccfDNA fragments in the short fraction, and sequencing the ccfDNA fragments in the short fraction to generate sequenced ccfDNA fragments.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: August 17, 2021
    Assignee: University of Utah Research Foundation
    Inventor: Hunter R. Underhill
  • Publication number: 20210238590
    Abstract: Methods of minimizing dysregulation of Staufen1-associated RNA metabolism can include introducing an amount of a Staufen1-regulating agent to a target cell sufficient to minimize the dysregulation. Therapeutic compositions for treating a neurodegenerative condition associated with Staufen1-induced dysregulation of RNA metabolism can include a therapeutically effective amount of a Staufen1-regulating agent and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: June 14, 2019
    Publication date: August 5, 2021
    Applicant: University of Utah Research Foundation
    Inventors: Stefan M. Pulst, Daniel R. Scoles, Sharan Paul
  • Patent number: 11079384
    Abstract: The present invention provides biomarker compositions and methods for the diagnosis and prognosis of PDAC. In a particular embodiment, the invention provides methods and compositions for screening, diagnosis and prognosis of early stage, asymptomatic PDAC.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: August 3, 2021
    Assignee: University of Utah Research Foundation
    Inventors: Sean J. Mulvihill, Matthew A. Firpo